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Background: Deterioration in walking ability characterized by slow walking speed is associated with an increased
risk of mortality in patients on hemodialysis (HD), but few studies have examined the potential for walking speed to
reduce the incidence of clinical events. In this study, we assessed a range of maximum walking speeds (MWS) with
regard to their capacity to reduce cardio-cerebrovascular events in HD patients.
Methods: In total, 188 Japanese outpatients (90 men, 98 women; mean age, 65 years) undergoing maintenance
HD three times a week were monitored for 7 years. We measured clinical characteristics and MWS at baseline and
followed these patients to track any cardio-cerebrovascular events. Patients were divided into quartiles (Q1 = lowest,
Q4 = highest) based on MWS for each sex. Cox proportional hazards regression and Kaplan-Meier estimates were
used to assess the contribution of MWS to cardio-cerebrovascular events.
Results: During the follow-up period, cardio-cerebrovascular events occurred in 42 patients. After adjusting for
potential confounders, the hazard ratio for events per 10 m/min increase in MWS was 0.77 (95 % confidence
interval: 0.65–0.92; P = 0.004). Seven-year cumulative incidence rates were 36, 32, 13, and 9 % for Q1 through Q4,
respectively, and a significant difference across MWS quartiles was observed (P < 0.001). While the incidence rates
did not significantly differ between Q1 and Q2 or between Q3 and Q4, Kaplan-Meier curves clearly differed
between Q2 and Q3.
Conclusions: Our findings suggest that more than the MWS level of Q3 (≥89 m/min in men and ≥85 m/min in
women) may serve as important MWS values for disease management in ambulatory HD patients.
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Many recent clinical reports have demonstrated that
motor function including walking ability can deteriorate
significantly in patients with end-stage renal dysfunction
who require hemodialysis (HD), compared to age-
matched community-based healthy individuals [1, 2]. In* Correspondence: atsuhikonet@gmail.com
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duced physical activity, decline in instrumental activities
of daily living, and overall lower quality of life [3–5].
Moreover, epidemiological cohort studies have found
that slow walking speed is independently associated with
mortality, hospitalization, and adverse events in healthy
older individuals and in patients with heart disease, kid-
ney disease, stroke, and other chronic diseases [4–7].
From a clinical perspective, it is necessary to evaluate
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the elderly) with chronic diseases that may require HD.
Overall, survival of patients with end-stage renal dys-
function has been improving annually over the past dec-
ade, regardless of whether HD or peritoneal dialysis is
provided as treatment. This is because dialysis treatment
technology and disease management for patients under-
going dialysis have made great progress in recent years
[8]. Despite this, the percentage of elderly HD patients
who are 60 years or older has reached 75 % in Japan [9].
Accordingly, HD patients are more likely to have de-
creased walking speed due to age-related loss of muscle
mass (sarcopenia), as well as decreased muscle strength
and balance function due to reduced physical activity
[10]. In addition, patients who have undergone HD for
10 years or more comprise one third of all HD patients
[9]. After regular HD treatment is initiated, these
patients are also more likely to develop multiple comor-
bidities including ischemic heart disease, peripheral vas-
cular disease, stroke, and orthopedic disease, to name a
few, in addition to the primary cause of their end-stage
renal dysfunction. Thus, HD patients have a 10 to 20
times higher risk for cardio-cerebrovascular events com-
pared to age-matched healthy people [11]. However, very
few studies have conducted longitudinal evaluations of
walking speed associated with subsequent clinical events
in HD patients, and optimal management techniques for
walking speed in these patients remain unclear. Given
the above, we conducted a 7-year cohort study to evalu-
ate a range of walking speeds with regard to their cap-




This study was approved by the Ethics Committee of
Kitasato University School of Allied Health Sciences and
was conducted in accordance with the standards set
forth by the latest revision of the Declaration of Helsinki.
All patients received a detailed explanation of the study
protocol and provided informed consent. From October
2002 to September 2014, clinically stable outpatients at
the Hemodialysis Center at Sagami Junkanki Clinic were
assessed for eligibility for inclusion in this prospective
study. Patients were undergoing maintenance HD ther-
apy three times a week according to the Japanese Society
for Dialysis Therapy guidelines. In order to focus specif-
ically on how walking ability impacts subsequent cardio-
cerebrovascular events, subjects were excluded if they
fulfilled the following criteria: duration of maintenance
HD ≤3 months; hospitalization ≤6 months prior to study
enrollment; history of recent myocardial infarction or an-
gina pectoris; presence of uncontrolled cardiac arrhythmias,
hemodynamic instability, or uncontrolled hypertension;require walking assistance; and the presence of any other
conditions that limited walking (e.g., dementia, low vision
or blindness, paralysis due to stroke, leg amputation).
Demographic and clinical factors
Information on demographic factors (age, sex, HD dur-
ation), physical characteristics (body mass index [BMI]),
primary kidney disease, and comorbid conditions was
collected at study entry. Blood hemoglobin, serum albu-
min, and serum C-reactive protein were obtained from
patient hospital charts. To quantify comorbid illnesses in
this study, we used a comorbidity index developed for
dialysis patients (composed of primary causes of end-
stage renal disease; atherosclerotic heart disease, con-
gestive heart failure, cerebrovascular accident/transient
ischemic attack, peripheral vascular disease, dysrhyth-
mia, and other cardiac disease; chronic obstructive pul-
monary disease; gastrointestinal bleeding; liver disease;
cancer; and diabetes). This score was calculated using a
previously described method that has been used to
analyze survival among HD patients [12].
Maximum walking speed
Self-selected maximum walking speed (MWS) along a
10-m walkway was measured to assess patient walking
ability before dialysis on a dialysis day. The validity and
reliability of the 10-m walk test, which measures the
time (in seconds or minutes) required for a patient to
walk 10 m, have been investigated in several populations
including healthy elderly, patients with neurological
disorders, and those with orthopedic dysfunction [13].
First, patients were asked to walk down a 10-m walking
lane with an acceleration area at their usual speed to
prepare for the MWS measurement. They were then
instructed to walk as fast as was safely possible, without
running. MWS was defined as the higher value of two
attempts and expressed as the ratio of distance to time
(m/min) [13].
Cardio-cerebrovascular events
We assessed cardio-cerebrovascular events as an indica-
tor of subsequent adverse outcomes for HD patients. Pa-
tients were followed until the following clinical events
occurred during the 7-year cohort study: hospital admis-
sion for angina, myocardial infarction, heart failure, cere-
bral infarction, or cerebral hemorrhage. Diagnoses for
primary admission were recorded using the International
Classification of Disease, version 10 (ICD-10). Angina,
myocardial infarction, and heart failure were defined as
ICD-10 codes I20-I22 and I50, respectively, and cerebral
infarction and cerebral hemorrhage as ICD-10 codes
I60-I63. Angina was defined using ICD-10 codes as fol-
lows: I20, angina pectoris; I20.0, unstable angina; I20.1,
angina pectoris with documented spasm; I20.8, other
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specified. Myocardial infarction was defined using ICD-
10 codes as follows: I21, acute myocardial infarction;
I22, subsequent myocardial infarction; I21.0, acute trans-
mural myocardial infarction of anterior wall; I21.1, acute
transmural myocardial infarction of inferior wall; I21.2,
acute transmural myocardial infarction of other sites;
I21.3, acute transmural myocardial infarction of unspeci-
fied site; I21.4, acute subendocardial myocardial infarc-
tion; I21.9, acute myocardial infarction unspecified;
I22.0, subsequent myocardial infarction of anterior wall;
I22.1, subsequent myocardial infarction of inferior wall;
I22.8, subsequent myocardial infarction of other sites;
and I22.9, subsequent myocardial infarction of unspeci-
fied site. Heart failure was defined using ICD-10 codes
as follows: I50, heart failure; I50.0, congestive heart
failure; I50.1, congestive heart failure; and I50.9, heart
failure, unspecified.
Statistical analysis
As there are no established MWS categories for HD pa-
tients, MWS was categorized into sex-specific quartiles
based on previous studies that found a strong associ-
ation between MWS and sex. Patients were divided into
following quartiles, ranging from Q1 (slow MWS) to Q4
(fast MWS): <79, 79 to 89, 89 to 105, and ≥105 m/min
in men and <72, 72 to 85, 85 to 100, and ≥100 m/min in
women. Differences in clinical characteristics and MWS
between quartiles were tested by one-way analysis of
variance, Kruskal-Wallis test, or chi-squared test. A
multivariable analysis was performed using the Cox
proportional hazards regression model to estimate the
independent prognostic effect of MWS on risk of subse-
quent cardio-cerebrovascular events after adjusting for
confounders. We included the confounders (MWS, age,
sex, BMI, HD duration, diabetic nephropathy of primary
kidney disease, comorbidity score, hemoglobin, serum
albumin, and serum C-reactive protein) in the models.
Within the present study sample, there were 42 cardio-
cerebrovascular events, which allowed for a maximum
of four variables to be included in the multivariate Cox
model. If the multivariate Cox model includes more than
four covariates, it has the potential to cause overfitting.
To avoid overfitting, all potential confounding factors
were reduced to four composite characteristics with a
significant (P < 0.05) association with subsequent
cardio-cerebrovascular events in the univariate Cox
model. We calculated the cumulative incidence of cardio-
cerebrovascular events according to MWS quartiles.
Kaplan-Meier analysis was used to estimate long-term ef-
fects. The log-rank test was used to examine differences in
the risk of subsequent cardio-cerebrovascular events be-
tween MWS quartiles. The 7-year cumulative incidence
probability was estimated using the life table method withthe interval length set at 1 month. All analyses were
performed using the Statistical Package for Social Sciences
(SPSS Statistics 22.0 for Mac; IBM Corp., Armonk, NY,
USA). Statistical significance was set at P < 0.05.Results
Patient characteristics
Of the 465 Japanese outpatients assessed for their eli-
gibility for inclusion, we excluded 119 patients who
did not satisfy the inclusion criteria, and 158 patients
declined to participate in the study. Ultimately, 188
HD patients were recruited (Fig. 1). Demographic and
clinical characteristics of the patients are summarized
in Table 1. The patients comprised 90 men and 98
women, aged 35–88 years (mean age, 65 years). The
HD duration was 3.3 (25th, 75th percentiles, 1.4, 9.5)
years at baseline. The most common underlying kid-
ney diseases were diabetic nephropathy (33.5 %),
followed by glomerulonephritis (32.4 %). Mean co-
morbidity score was 4.8 ± 3.0, and MWS for all pa-
tients was 87.5 ± 19.6 m/min. Table 1 shows the
baseline characteristics of the patients according to
MWS quartiles 1–4. We found significant quartile-
dependent differences in age, comorbidity score,
serum albumin, and MWS (P < 0.01, P < 0.01,
P = 0.02, P < 0.001 respectively). Other baseline char-
acteristics did not differ significantly across the four
quartiles.Outcomes
Patients were followed for up to 7 years. The overall
follow-up durations ranged from 1 to 84 months (me-
dian, 53 months). During the follow-up period, cardio-
cerebrovascular events occurred in 42 patients (22 %): 8
of angina, 12 of myocardial infarction, 16 of heart fail-
ure, 1 of subarachnoid hemorrhage, 1 of intracerebral
hemorrhage, and 4 of cerebral infarction. Twenty-five
percent of the patients with Q1 and Q2 group occurred
events after 21 and 40 months. On the other hand, the
events rate of patients with Q3 and Q4 at the end of the
follow-up was less than 25 %.The relationship between outcomes and MWS as
continuous variables
According to the Cox proportional hazards model, the
increase in crude hazard ratio (HR) of MWS per 10 m/
min was 0.74 (95 % confidence interval [CI], 0.63–0.86;
P < 0.001), which indicated that maintaining a higher MWS
was associated with a reduction in cardio-cerebrovascular
events (Table 2). After adjusting for the effects of age,
diabetic nephropathy, and comorbidity score, the HR was
0.77 (95 % CI, 0.65–0.92; P = 0.004) (Table 2).
Fig. 1 Flow diagram for patient selection and exclusion
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categorical variables
Seven-year cumulative incidence rates were 36, 32, 13,
and 9 % for Q1 through Q4, respectively (P < 0.001). The
cumulative incidence rates of cardio-cerebrovascular
events in Q1 were significantly higher than those in Q3
and Q4 (P = 0.003, P < 0.001, respectively). Cumulative
incidence rates of cardio-cerebrovascular events in Q2
were also significantly higher than rates in Q3 and Q4
(P = 0.03, P = 0.004, respectively). While incidence rates
did not significantly differ between Q1 and Q2 or be-
tween Q3 and Q4, Kaplan-Meier curves showed clear
differences between Q2 and Q3 (Fig. 2).
Discussion
The main finding of this study is that the initial MWS at
the time of study entry significantly influenced the 7-
year cumulative incidence of cardio-cerebrovascular
events in ambulatory patients on hemodialysis (HD),
independent of age, sex, BMI, HD duration, diabetic
nephropathy of primary kidney disease, comorbid condi-
tions, and markers of anemia, nutrition, and inflamma-
tion. To our knowledge, this is the first study todemonstrate an association between walking ability and
subsequent cardio-cerebrovascular events in an Asian
population of patients with chronic kidney disease
undergoing HD. Based on our findings, the hazard ratio
for clinical events per 10-m/min increases in MWS was
0.77. Our study also revealed that male HD patients with
MWS ≥89 m/min and female HD patients with MWS
≥85 m/min at baseline had a significantly lower cumula-
tive incidence of cardio-cerebrovascular events com-
pared to other patients during the 7-year follow-up
period. These different walking speeds had not yet been
evaluated for their potential to reduce subsequent clin-
ical events in ambulatory HD patients. As such, our
present study findings have important implications with
regard to effective disease management in Japanese HD
populations.
Recent studies have shown that walking speed is gain-
ing interest for the prognosis of adverse health-related
events, particularly for elderly individuals. Montero-
Odasso et al. showed that a slow walking speed alone in
otherwise well-functioning elderly individuals was
enough to predict the risk for future adverse events dur-
ing a 2-year follow-up study [5]. A recent 7-year cohort
Table 1 Baseline characteristics based on levels of maximum walking speed
Characteristic Overall
(n = 188)
Maximum walking speed P
valueQ1 (n = 47) Q2 (n = 47) Q3 (n = 47) Q4 (n = 47)
Age (years) 65 (10) 73 (10) 64 (8) 63 (9) 60 (9) <0.001
Women 98 (52.1) 24 (51) 25 (53) 24 (51) 25 (53) 0.99
Body mass index (kg/m2) 21.2 (3.2) 20.3 (3.2) 21.7 (3.3) 20.7 (3.3) 21.9 (2.8) 0.42
Hemodialysis duration (years) 3.3 (1.4, 9.5) 2.5 (1.2, 8.1) 3.8 (2.0, 12.6) 3.2 (1.8, 7.3) 3.3 (1.0, 8.5) 0.35
Primary kidney disease 0.19
Diabetic nephropathy 63 (33.5) 17 (36.2) 17 (36.2) 16 (34.0) 13 (27.7)
Glomerulonephritis 61 (32.4) 9 (19.1) 15 (31.9) 18 (38.3) 19 (40.4)
Hypertension 16 (8.5) 4 (8.5) 5 (10.6) 4 (8.5) 3 (6.4)
Polycystic renal disease 7 (3.7) 1 (2.1) 0 (0) 4 (8.5) 2 (4.3)
Other nephropathies 41 (21.8) 16 (34.0) 10 (21.3) 5 (10.6) 10 (21.3)
Comorbid condition
Presence of cardiac diseasea 91 (48.4) 31 (66.0) 20 (42.6) 26 (55.3) 14 (29.8) 0.003
Peripheral vascular disease 20 (10.6) 7 (3.7) 5 (2.7) 4 (2.1) 4 (2.1) 0.72
Presence of diabetes mellitus 76 (40.4) 19 (40.4) 22 (46.8) 18 (38.3) 17 (36.2) 0.74
Comorbidity score 4.8 (3.0) 6.3 (2.8) 4.7 (3.0) 4.4 (2.9) 3.6 (2.7) <0.001
Laboratory values
Hemoglobin (g/dL) 10.3 (1.0) 10.2 (0.9) 10.0 (1.0) 10.3 (0.9) 10.4 (1.0) 0.34
Serum albumin (g/dL) 3.9 (0.3) 3.8 (0.3) 3.8 (0.3) 3.9 (0.3) 4.0 (0.3) 0.02
Serum C-reactive protein (mg/dL) 0.3 (0.7) 0.4 (0.8) 0.3 (0.7) 0.3 (0.7) 0.3 (0.4) 0.61
Walking ability
Maximum walking speed (m/min) 87.5 (19.6) 62.7 (11.6) 81.4 (4.9) 94.1 (5.6) 111.9 (8.1) <0.001
Values are expressed as mean (standard deviation), median (25th, 75th percentiles), or number (percentage of total). The cutoff values defining the maximum
walking speed quartiles were <79, 79–89, 89–105, and ≥105 m/min in men and <72, 72–85, 85–100, and ≥100 m/min in women
aHistory of coronary disease, congestive heart failure, myocardial infarction, or other cardiac disease
Table 2 Univariate and multivariate Cox models for the effects of maximum walking speed on cardio-cerebrovascular events
Factors Units of
increase
Univariate Cox modela Multivariate Cox modelb
HR (95 % CI) P HR (95 % CI) P
Maximum walking speed 10 m/min 0.74 (0.63–0.86) <0.001 0.77 (0.65–0.92) 0.004
Age (years) 1 year 1.05 (1.01–1.08) 0.006 1.03 (0.99–1.07) 0.16
Men (vs. women) – 0.60 (0.33–1.11) 0.10
Body mass index 1 kg/m2 1.03 (0.93–1.13) 0.61
Hemodialysis duration 1 year 1.01 (0.97–1.05) 0.70
Diabetic nephropathy (presence) 1 presence 1.96 (1.06–3.60) 0.03 1.93 (1.02–3.64) 0.04
Comorbidity score 1 1.11 (1.01–1.21) 0.04 1.02 (0.92–1.14) 0.70
Hemoglobin 0.1 g/dL 1.15 (0.85–1.56) 0.35
Serum albumin 0.1 g/dL 0.42 (0.17–1.05) 0.06
Serum C-reactive protein 0.1 mg/dL 1.21 (0.85–1.73) 0.30
Analyses were performed using a Cox proportional hazards regression model
HR hazard ratio, CI confidence interval
aUnadjusted for clinicopathological factors of cardio-cerebrovascular events
bAdjusted for age, diabetic nephropathy, and comorbidity score
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Fig. 2 Kaplan-Meier estimates for cumulative incidence rates of subsequent cardio-cerebrovascular events according to maximum walking speed
quartiles
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that those who walked slowly had an almost threefold
higher risk for cardiovascular mortality compared to
those who walked faster [6]. Several clinical studies have
found that a slow walking speed is significantly associ-
ated with an increased risk of subsequent cardiovascular
events in elderly patients with ischemic heart disease, in-
dependent of cardiac function and comorbid conditions
[14–17]. In addition, a slow walking speed was used as
an indicator of frailty or geriatric conditions as well as
decreased muscle strength (weak grip), cognitive impair-
ment, and depression [16, 17]. Our findings are consist-
ent with those reported by previous studies of elderly
patients with chronic heart disease. Characteristics of
HD patients enrolled in our present study were as fol-
lows: elderly with a mean age of 65 years (range 35–
88 years), long disease duration with a median time on
HD of 3.3 years (range 0.3–31.2 years), and decreased
physical function with a mean MWS of 87.5 m/min
(range 33.2–139.2 m/min) as much as patients with
chronic heart disease [14]. Physical function including
walking speed among HD patients reportedly decreases
year after year and tends to have already deteriorated
somewhat since before the initiation of HD treatment
[18, 19]. Therefore, it is clinically necessary to evaluate
and manage walking speed in order to implement effect-
ive disease management for HD patients.
The association of slow walking speed with increased
risk of cardio-cerebrovascular events in the present
study can be explained primarily in terms of the rela-
tionship between walking speed and physical activity.Those who walk fast likely tend to maintain high levels
of habitual physical activity of daily living. Kumahara
et al. reported that walking speed was significantly asso-
ciated with daily physical activity in healthy people aged
18–64 years [3]. Several other studies indicated that high
levels of physical activity were associated with a de-
creased risk of subsequent cardio-cerebrovascular events
in healthy older adults [20, 21]. We found in previous
studies that a lower level of habitual physical activity is
an independent risk factor for all-cause mortality and is
closely associated with slow MWS in maintenance HD
patients [13, 22]. Several previous studies also revealed
that HD patients who increased their level of physical
activity were able to improve risk factors for cardio-
cerebrovascular disease, such as hypertension, arterial
stiffness, inflammatory reaction, vascular endothelial
function, high levels of plasma triglycerides and low
levels of high-density lipoprotein cholesterol, dysfunc-
tion of the cardiac autonomic nervous system, and re-
duced maximal oxygen consumption [22–24]. These
reports suggest that maintaining high levels of habitual
physical activity by walking at a fast speed can help pre-
vent the development of atherosclerotic vascular disease
and avoid complications from atherosclerotic vascular
disease. The main findings of the present study regard-
ing the association between slow walking speed and sub-
sequent poor outcomes are consistent with findings
noted in previous reports.
In our 7-year follow-up study, we also assessed the re-
lationship between levels of MWS (divided into quartiles
for each sex) and subsequent cardio-cerebrovascular
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may comprise a part of effective disease management for
the prevention of events. Kaplan-Meier curves clearly
differed between Q2 and Q3 (regardless of an MWS
≥89 m/min in men and ≥85 m/min in women), while no
significant difference was found between Q3 and Q4
(regardless of an MWS ≥105 m/min in men and
≥100 m/min in women). A recent cohort study of walk-
ing speed with a 5-year follow-up period reported that
community-dwelling elderly people (aged ≥65 years)
with a slow walking speed (≤90 m/min for men and ≤
81 m/min for women) had a higher risk for cardiovascu-
lar mortality compared to those with a fast walking
speed [6]. Yamamoto et al. also showed that ischemic
heart disease patients with a fast walking speed (>90 m/
min for men and >81 m/min for women) at baseline had
a significantly lower cumulative incidence of cardiac
events compared to other participants during a 3-year
follow-up study [15]. Findings from these studies are
fairly consistent with our results. We would therefore
surmise that MWS above that for Q3 (MWS ≥89 m/min
in men and ≥85 m/min in women) would be a suitable
walking speed for disease management in HD patients.
A colleague of ours and Yamamoto have reported that
the walking speed of age- and sex-matched healthy eld-
erly people from the same geographic region as the
present study was almost more than the MWS level of
Q3; specifically, no healthy males had a MWS less than
90 m/min, and no healthy females had a MWS less than
81 m/min [14]. Accordingly, anything above the Q3
MWS was thought to be a relatively attainable MWS for
elderly HD patients because the lowest value within Q3
is likely to represent the lower limit for MWS among
healthy elderly people. MWS above that for Q3 is also a
reasonable MWS that should be achieved in order to
walk to regular visits at an outpatient clinic for success-
ful and continual HD treatment, maintain instrumental
activities of daily living (e.g., outside social activities, out-
ings, etc.), and maintain quality of life for an elderly HD
outpatient. In addition, previous studies have found that
leg strength and standing balance function are independ-
ently associated with walking speed in ambulatory HD
patients [25]. Therefore, improvements in MWS could
be achieved in HD patients showing a low MWS with
exercising guidance aimed at promoting improved daily
physical activity, and/or resistance training to improve
leg strength and balance function.
This study had some limitations. First, because it was
an observational study, residual confounders may re-
main. Second, given the study design, causality cannot
be established. Thus, additional randomized and con-
trolled studies are needed. To the best of our knowledge,
this is the first study to show the correlation between
cardio-cerebrovascular events and MWS in HD patients.Third, because we evaluated MWS of HD patients only
at baseline, temporal fluctuations in walking abilities
were not evaluated. However, because we recruited clin-
ically stable and adequately dialyzed patients, their walk-
ing ability was assumed not to fluctuate dramatically.
Fourth, we excluded patients who needed assistance with
walking. As a result, comorbid conditions in the patients
were relatively mild. These limitations should be consid-
ered when generalizing our study results to more se-
verely limited patients. Finally, this was a small-scale
observational study, so our results may lack general
applicability.
Conclusions
Our 7-year follow-up study revealed that a slow walking
speed was significantly and independently associated with
an increased risk of subsequent cardio-cerebrovascular
events. In addition, we found that MWS ≥89 m/min for
males and MWS ≥85 m/min for females might serve as
important MWS values for disease management in HD
patients.
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